Targeting the leptin receptor: A potential new mode of treatment for breast cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 8, 2011, Pages 1147-1150

  Otvos, Laszlo ^a,b   Surmacz, Eva ^a,b  

^a TEMPLE UNIVERSITY   (United States)

^b Peptherx Inc   (United States)

Author keywords

adipokine; antagonist; peptide based drugs; pluripotent target; triple negative breast cancer

Indexed keywords

ALLOACA; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; CISPLATIN; DASATINIB; ERLOTINIB; ESTROGEN RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; INIPARIB; LAPATINIB; LEPTIN; LEPTIN RECEPTOR; LEPTIN RECEPTOR BLOCKING AGENT; PLATINUM COMPLEX; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TIGATUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; HUMAN; IC 50; METASTASIS INHIBITION; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, LEPTIN;

EID: 80052331618     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.109     Document Type: Review

References (28)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, Atlanta, GA, USA (2010).
3. Orlando L, Schiavone P, Fedele P et al. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat. Rev. 36, S67-S71 (2010).
4. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 406, 747-752 (2000).
5. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 17, 173-176 (2008).
6. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 12(S2), S3 (2010).
7. De Ruijter TC, Weeck J, de Hoon JPJ et al. Characteristics of triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 137, 183-192 (2011).
8. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: A review. J. Womens Health 18, 883-893 (2009).
9. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast Cancer 9, S73-S81 (2009).
10. Davies E, Hiscox S. New therapeutic approaches in breast cancer. Maturitas 68, 121-128 (2011).
11. Cleary MP, Grossmann ME, Ray A. Effect of obesity on breast cancer development. Vet. Pathol. 47, 202-213 (2010).
12. Porter GA, Inglis KM, Wood LA et al. Effect of obesity on presentation of breast cancer. Ann. Surg. Oncol. 13, 327-332 (2006).
13. Surmacz E. Obesity hormone leptin: A new target in breast cancer? Breast Cancer Res. 9, 301 (2007).
14. Otvos L Jr, Kovalszky I, Riolfi M et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur. J. Cancer 47, 1578-1584 (2011).
15. McMurtry V, Simeone AM, Nieves-Alicea R et al. Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells. Clin. Exp. Metastasis 26, 197-204 (2009).
16. Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev. 20, 193-201 (2009).
17. Fusco R, Galgani M, Procaccini C et al. Cellular and molecular crosstalk between leptin receptor and estrogen receptor - a in breast cancer: Molecular basis for a novel therapeutic setting. Endocr. Relat. Cancer 17, 373-382 (2010).
18. Fiorio E, Mercanti A, Terrasi M et al. Leptin/HER2 crosstalk in breast cancer: In vitro study and preliminary in vivo analysis. BMC Cancer 8, 305 (2008).
19. Ray A, Cleary MP. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin. Ther. Targets 14, 443-51 (2010).
20. Peelman F, Van Beneden L, Zabeau H et al. Mapping of the leptin binding sites and design of a leptin antagonist. J. Biol. Chem. 279, 41038-41046 (2004).
21. Elinav E, Niv-Spector L, Katz M et al. Pegylated leptin antagonist is a potent orexigenic agent: Preparation and mechanism of activity. Endocrinology 150, 3083-3091 (2009).
22. Shpilman M, Niv-Spector L, Katz M et al. Development and characterization of high affinity leptins and leptin antagonists. J. Biol. Chem. 286, 4429-4442 (2011).
23. Gonzalez R, Watters A, Xu Y et al. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 11, R36 (2009).
24. Otvos L Jr, Terrasi M, Cascio S et al. Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochim. Biophys. Acta 1783, 1745-1754 (2008).
25. Otvos L Jr, Kovalszky I, Scolaro L et al. Peptide-based receptor antagonists for cancer treatment and appetite regulation. Biopolymers 96, 117-125 (2011).
26. Ferla R, Bonomi M, Otvos L Jr et al. Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: Comparison with VEGF effects. BMC Cancer (2011) (In Press).
27. Otvos L Jr, Shao W-H, Vanniasinghe A et al. Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis. Peptides DOI: 10.1016/j.peptides.2011.06.015 (2011) (Epub ahead of print).
28. Hanson LR, Frey WH 2nd. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J. Neuroimmune Pharmacol. 2, 81-86 (2007).